Artesunate Suppositories

Phase 1Small molecule

SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Artesunate Suppositories is one of 30 small molecule programs targeting Intraepithelial Neoplasia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intraepithelial NeoplasiaActive, not recruiting

Cervical Intraepithelial NeoplasiaActive, not recruiting

Intraepithelial NeoplasiaPhase 1

Active, not recruiting

Cervical Intraepithelial NeoplasiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Cervical Intraepithelial Neoplasia

#DrugCompanyPhaseTrials

Taxol

Prometrium

Aldara

BBausch Health Americas, Inc.

Phase 3

5 4

Keytruda

Merck & Co.

Phase 2

1 5

Ornidyl

UUSWM, LLC (dba US WorldMeds)

Phase 2

1 6

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 7

Viracept

AAgouron Pharmaceuticals

Phase 2

1 8

Hepatitis B Adjuvanted Vaccine

GSK

Phase 3

1 9

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

1 10

Adrucil

EElorac, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intraepithelial Neoplasia1 trial

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

Completed·JJohns Hopkins University·Phase 1·NCT03100045·18 enrolled

Cervical Intraepithelial Neoplasia1 trial

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02354534·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Artesunate Suppositories. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Artesunate Suppositories compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Artesunate Suppositories. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Artesunate Suppositories

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intraepithelial Neoplasia1 trial

Cervical Intraepithelial Neoplasia1 trial

References

Drug Info

Quick Facts

Related News